%3Amax_bytes(150000)%3Astrip_icc()%2FTAL-snake-warning-sign-HIKESNAKEBITE0625-f8d9e14b84fd48b6a545019fbb5e1ab3.jpg&w=3840&q=100)
This Teen 'Felt a Prick' On a Fishing Trip Only to Discover a Rattlesnake Bite
Zain Shah was bitten by a rattlesnake on the banks of Lost Cove Creek during a high-school fishing trip in the mountains of western North Carolina. The North Carolina Emergency Management (NCEM) announced in a press release that responders in Avery County successfully rescued the hiker, who was transferred to the hospital to receive medical treatment.
The group was about to head back for the day and 17-year-old Zain had just stepped over a log when he felt a prick on his heel. When he looked, he saw a timber rattlesnake sitting nearby. He is currently recovering.
'I'm beyond grateful for the incredible NCHART and Linville-Central Rescue teams, who got to them in the middle of nowhere and saved his life! He was air-lifted to and treated at Johnson City Medical Center, TN, and is now recovering at home,' his father, Imran Shah, said in a Facebook post.
If you are bitten by a snake, it's important to call 911 and go to the closest emergency department to make sure that the snake isn't venomous. 'If someone in your party can take a photo while staying a good distance away, that could be helpful in identifying the snake," Maggie Peikon, manager of communications at the American Hiking Society, told Travel + Leisure .
Try your best to stay calm and minimize activity if possible,' added Peikon.
It's important to keep the bite below the level of the heart, and avoid drinking alcohol and pain relievers, which can thin your blood. Also, if you are bitten, you should not try to suck the venom out with your mouth or any kind of suction device, as it can lead to an infection.
'If you are bitten on the arm or hand, remove any constricting clothing, rings, bracelets, etc. in case your arm swells. Do not apply a constriction band or tourniquet with a belt or rope. Do not apply either hot or cold packs,' Peikon said. 'If you have a pen or marker on you, circle the area where you were bitten and take note of the time of the bite—this will help monitor swelling and rate of changes.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology
BMI OrganBank is developing novel medical devices with potential to significantly reduce the waitlist for lifesaving organ transplants, beginning with kidneys FDA Breakthrough Device Designation secures expedited FDA engagement in advance of clinical studies planned for early next year WINSTON-SALEM, N.C., Aug. 4, 2025 /PRNewswire/ -- BMI OrganBank, a pioneering leader in organ assessment and preservation, proudly announces that its revolutionary organ preservation device has received the prestigious Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This designation, granted for their kidney preservation device, underscores BMI OrganBank's commitment to advancing transformative technologies that will significantly improve outcomes for transplant patients. With current kidney perfusion technologies, which use cold storage temperatures, it is difficult to evaluate the function of kidneys before transplant. Furthermore, they are vulnerable to significant injury during the storage period before transplantation. As such, a large proportion of donated kidneys remain unused. BMI OrganBank's groundbreaking room temperature machine perfusion (RTMP) platform, developed in collaboration with leading transplant surgeons and academic medical centers, shows great promise to facilitate kidney quality assessment and extend preservation times. BMI OrganBank intends to increase the number of kidneys available for transplant and address stubbornly long kidney transplant waitlist times. A clinical study is planned for early next year. "We are incredibly honored to receive this significant designation from the FDA and look forward to working with them as we prepare for clinical studies" stated Carrie DiMarzio, Chief Executive Officer and Co-Founder. David A. Gerber, MD, abdominal transplant surgeon and Chief Medical Officer stated "We are energized by our promising preclinical data. The timing of this news is outstanding as my colleagues and I participate in the World Transplant Congress this week." About BMI OrganBank® BMI OrganBank specializes in developing transformative perfusion systems for organ and tissue evaluation and preservation. With facilities at the Innovation Quarter in Winston-Salem, NC, and Research Triangle Park, NC, the company is advancing multiple medical devices that use its patented and proprietary technologies. Its flagship product, the portable OrganBank kidney device, was co-developed with leading transplant surgeons and is set to begin clinical studies soon. Learn more at View original content to download multimedia: SOURCE BMI OrganBank Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
9 hours ago
- Associated Press
BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology
WINSTON-SALEM, N.C., Aug. 4, 2025 /PRNewswire/ -- BMI OrganBank, a pioneering leader in organ assessment and preservation, proudly announces that its revolutionary organ preservation device has received the prestigious Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This designation, granted for their kidney preservation device, underscores BMI OrganBank's commitment to advancing transformative technologies that will significantly improve outcomes for transplant patients. With current kidney perfusion technologies, which use cold storage temperatures, it is difficult to evaluate the function of kidneys before transplant. Furthermore, they are vulnerable to significant injury during the storage period before transplantation. As such, a large proportion of donated kidneys remain unused. BMI OrganBank's groundbreaking room temperature machine perfusion (RTMP) platform, developed in collaboration with leading transplant surgeons and academic medical centers, shows great promise to facilitate kidney quality assessment and extend preservation times. BMI OrganBank intends to increase the number of kidneys available for transplant and address stubbornly long kidney transplant waitlist times. A clinical study is planned for early next year. 'We are incredibly honored to receive this significant designation from the FDA and look forward to working with them as we prepare for clinical studies' stated Carrie DiMarzio, Chief Executive Officer and Co-Founder. David A. Gerber, MD, abdominal transplant surgeon and Chief Medical Officer stated 'We are energized by our promising preclinical data. The timing of this news is outstanding as my colleagues and I participate in the World Transplant Congress this week.' About BMI OrganBank® BMI OrganBank specializes in developing transformative perfusion systems for organ and tissue evaluation and preservation. With facilities at the Innovation Quarter in Winston-Salem, NC, and Research Triangle Park, NC, the company is advancing multiple medical devices that use its patented and proprietary technologies. Its flagship product, the portable OrganBank kidney device, was co-developed with leading transplant surgeons and is set to begin clinical studies soon. Learn more at View original content to download multimedia: SOURCE BMI OrganBank
Yahoo
15 hours ago
- Yahoo
Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025
DURHAM, N.C., August 04, 2025--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the second quarter 2025 and provide a business update on August 7, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company's pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome e.g. viral DNA such as in the HBV program), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV such as in the DMD program). View source version on Contacts Investor and Media Contact: Naresh TannaVice President of Investor
